images (1)

nandrolone

The doses when administered under the lining of the brain.Adults:The dosages may largely depend on the chosen clinical problem, examination technique and the region.If you nandrolone have equipment to record the image in all projections without changing the patient’s body position and the introduction of contrast medium under fluoroscopic guidance, may be sufficient smaller volume of diagnostic products.

The recommended dose for the individual studies

 

  • myelography

The amount of drug Ultravist 240 mg iodine / ml up to 12.5 ml.

Maximum dose nandrolone corresponds to a total dose of 3 g of iodine and should not be more than one study.

After examining the contrast agent should be directed to the lumbar region, which is achieved by giving the patient pryamosidyaschego position or lifting the head on the bed at 15 ° C for at least 6 hours.

Children:
Safety and efficacy of Ultravist drug during myelography not been studied

 

  • Dose when administered into the body cavity

 

During the arthrography, hysterosalpingography  administration of the contrast agent should be administered under the control of fluoroscopy.

Recommended doses for individual studies:
The dose may vary depending on the age, body weight, general condition of the patient, as well as on the chosen clinical problem, used the technical equipment and the field survey. Below are the average dose recommended to adults OK.

 

  • arthrography:

 

5-15 ml Ultravist 240 mg iodine / ml / 300 mg iodine / ml / 370 mg iodine / ml

 

  • hysterosalpingography:

 

10-25 ml of Ultravist 240 mg iodine / ml

 

 

The dosage depends on the clinical problem and solved by the size of the rendered structure.

 

  • Other cavity:

 

The dosage depends on the clinical problem and solved by the size of the rendered structure.

Side effects
Side effects in the case of the use of intravascular iodinated contrast media are usually mild, moderate and transient in nature. However, severe and life-threatening reactions, not excluding fatal reactions, did take place.

Most often, when the intravascular use of such reactions such as nausea, vomiting, pain and a burning sensation.

Headache, including the case of a long and serious form of nausea and vomiting are common. Most adverse reactions after myelography or body cavities contrast occurs within a few hours after the administration of contrast agent.

 

  • ERCP

 

In addition to the listed undesirable effects during nandrolone may increase the level of pancreatic enzymes (often), the development of pancreatitis (rare).

Overdose
In acute toxicity studies in animals have not revealed the risk of acute intoxication following use of Ultravist drug.

 

  • Intravascular administration

 

Symptoms may include an imbalance of fluids and electrolytes, kidney failure, complications of the cardiovascular system and lungs. It is necessary to control the liquid level, electrolytes, renal function.Treatment of overdose should be directed at maintaining vital functions. Ultravist can be removed from the body by the dialysis. In case of a wrong dose in excess of intravascular injection of the drug into the human body, it is necessary to compensate for the loss of water and electrolytes by infusion. It is necessary to carry out monitoring of renal function of at least 3 days.

If necessary, it can be used to derive hemodialysis main part of contrast material from the human body.

 

  • Introduction under the lining of the brain

 

nandrolone phenylpropionate

Before the introduction of the vial should be inspected carefully. If you violate the integrity of the bottle, substantial color change, you notice visible particulate matter (including crystals) the drug should not be used. As Ultravist is a highly concentrated solution, crystallization (haze milky appearance and / or sediment or crystals in suspension) can occur very rarely.

For administration of the contrast agent solution is necessary to use an automatic injector or other special tools while maintaining sterility. Dial nandrolone phenylpropionate in a syringe or infusion pump must be immediately prior to administration.

You can not do more than one puncture the rubber stopper in order to avoid falling into the prepared solution of the cork of a large number of microparticles. It is therefore recommended to apply long-tipped cannula diameter not greater than nandrolone phenylpropionate (labeled best suited to the side opening of the cannula type Nocore-Admix) for puncturing the rubber plug and a set of contrast agent.

Unused after opening the vial of the drug solution should be destroyed.

Vials containing 200 or 500 ml of the drug should only be used for intravascular administration. For administration must use gnc genesis an automatic injector or other equipment that ensures the sterility of the drug.Follow the instructions on the use of auto injector or other equipment. Unused after opening the bottle can be used in preparation for the first 10 hours after opening. Then it should be destroyed.

Cartridges should be used in accordance with the accompanying hardware for use cartridges instructions. Unused to be destroyed after use of the drug solution cartridge.

Doses at the intravascular administration of intravascular contrast agent, if possible, it is better to exercise in finding the patient in the supine position.

In patients with severe renal or cardiovascular nandrolone phenylpropionate impairment, and in general poor health dose of the contrast agent should be as low as possible. In these patients, it is recommended to monitor renal function for at least 3 days after the test.

The dose of the contrast agent should be appropriate to the age, body weight, clinical problem solved and the method of research. The dosages given below are only to be regarded as guidelines; they represent the usual dose for an average adult weighing 70 kg. The value is expressed in ml doses for injection or once per kg body weight.

Typically, the dose to 1.5 grams of iodine per kg body weight is generally well tolerated. Between the individual organism injections should be given sufficient time for the liquid exiting the interstitial space for normalizing elevated serum osmolality. If necessary in some cases to exceed a total dose of 300 – 350 ml in adults shows the introduction of water and optionally trenbolone, electrolytes.

  • Intravenous DSA

For large vessels of nandrolone phenylpropionate solutions are used for injection 300 mg I / ml and 370 mg of iodine / ml in a volume of 30-60 ml. The drug is administered by bolus at a rate of 8-12 ml / s in the cubital vein or at a rate of 10-20 ml / s through the catheter in the vena cava. the contact time of contrast agent with the vein wall can be reduced, provided rapid bolus immediately after preparation Ultravist isotonic sodium chloride solution.

Adults 30-60 ml of solution for injection 300 mg I / ml solution for injection 370 mg of iodine per ml Ultravist drug.

  • intra-arterial

During the intra-arterial in contrast to conventional angiography can be administered to smaller amounts of the drug and its Ultravist lower concentrations.

  • Computed tomography

If possible, Ultravist should be injected intravenously as a bolus via the automatic injector. Only when slow scanning approximately half the dose should be administered bolus, and the rest within 2-6 minutes to guarantee a relatively constant concentration of drug in the blood.

Spiral nandrolone phenylpropionateand especially multi-layered allows you to receive a large amount of data in a single breath-hold. To obtain optimal diagnostic effect by intravenous bolus (80 – 150 ml solution for injection 300 mg I / ml Ultravist drug) in the surveyed area (peak time and duration of staining) it is recommended to use the automatic injector and to monitor the time interval trenbolone enanthate from the start of administration of the contrast agent to I start scanning

  • nandrolone phenylpropionate scan of the whole body

Required dose of the contrast agent and the rate of administration depend on the subject’s body, a problem solved by the diagnostic and especially from the differences in the duration and scan image reconstruction.

  • Intravenous urography

Due to the low concentration physiological ability immature kidney nephrons children requires relatively high doses of contrast agent.

The recommended dose of the drug Ultravist.

Take pictures of time. Take pictures as possible after administration Ultravist 300 mg iodine / ml / 370 mg iodine / mL for a duration of administration for 1-2 minutes (3-5 minutes after injection Ultravist 240 mg iodine / ml) up to 3 renal parenchyma -5 min (5-10 min after injection Ultravist 240 mg iodine / ml) for the visualization system of the renal pelvis and ureter – 8-15 minutes (12-20 minutes after injection Ultravist 240 mg iodine / ml) after initiation of administration of contrast agent. The younger the nandrolone phenylpropionate patient, the earlier picture is taken. Normally, you should take the first shot after 2-3 min after administration of contrast agent. In newborns, infants and patients with impaired renal function nandrolone phenylpropionate pictures at a later date can improve the visualization of the urinary tract.

npp cycle

Ultravist after intravascular injection is very rapidly distributed in the extracellular space. Its half-life period in the distribution phase is 3 minutes.

Communication with plasma proteins at a concentration . Ultravist can not penetrate the intact blood-brain barrier, but in a small amount passes through the placental barrier (shown in rabbits).

After 1 5 min after bolus intravenous administration npp cycle detected in plasma 28 ± 6% of the introduced quantity regardless of the dose. After the introduction of the shell under the maximum brain concentration of iodine in the plasma comprising 4.5% of the dose were observed after 3.8 hours.

  • Metabolism

After the introduction of Ultravist drug in clinically acceptable doses did not reveal its metabolites.

  • breeding

Withdrawal Iopromide in patients with normally functioning kidneys characterized by a time equal to the half-life of around 2 hours regardless of the dose. When using Ultravist drug in doses recommended for diagnostic purposes, it takes place solely by its glomerular filtration. 30 minutes after drug administration Ultravist kidneys displayed approximately 18% of the administered dose over 3 hours – 60% and in 24 hours – 92% respectively. Total clearance by using a low (1 150 mg / ml) and high (370 1 mg / ml) doses of 110 and 103 ml / min, respectively.

After lumbar myelography Ultravist is almost entirely excreted by the kidneys within 72 hours.

  • Violations of the liver and kidneys

Patients with end-stage renal failure, non-ionic contrast media can be eliminated by dialysis. Abnormal liver function does not affect the excretion of the drug Ultravist as 3 days in the feces allocated only 1.5% of the administered dose.

Indications The drug is intended for diagnostic purposes only!

Enhancing image contrast during computed tomography npp cycle, arteriography and venography, including intravenous / intra-arterial digital subtraction angiography ; intravenous urography, endoscopic retrograde cholangiopancreatography npp cycle, and arthrography research other body cavities.

– The solution for injection 240 mg iodine / ml:

Also, in the study of the subarachnoid space

– The solution for injection 370 mg iodine / ml:

It has special advantages in angiokardiografii

– Solutions for injection 300 mg I / ml and 370 mg iodine / mL are not recommended for subarachnoid space research.

Contraindications Absolute contraindications

Precautions These warnings and cautions apply to all routes of administration of the contrast agent, but noted the risk is higher when the intravascular administration.

  • Hypersensitivity, especially in the presence of severe cardiovascular diseases
  • Disorders of the thyroid gland
  • Elderly age
  • the patient’s serious condition

Intravascular administration

  • kidney damage

Nephrotoxicity caused by contrast media, which is a transient impairment of renal function, may occur after administration of Ultravist drug. In rare cases, acute renal failure may develop. Risk factors include, for example:

-predshestvuyuschaya renal failure, -degidratatsiya, -saharny diabetes -mnozhestvennaya myeloma / paraproteinemia, -povtornye and / or large doses of Ultravist drug.

  • Cardiovascular diseases

In patients with severe heart disease or severe coronary artery disease increased the risk of developing clinically significant hemodynamic changes and arrhythmia. In patients with valvular disease and pulmonary hypertension contrast medium administration may lead to pronounced hemodynamic disturbances. Reactions involving ischemic ECG changes and severe arrhythmias are most common in elderly patients and in patients with a history of cardiac pathology.

Intravascular administration of contrast media can cause pulmonary edema in patients with heart failure.

  • npp cycle

Patients with seizures in history or other disorders the risk of seizures may be increased or neurological complications in connection with the introduction of Ultravist drug.

  • pheochromocytoma

Patients with pheochromocytoma, there is the risk of hypertensive crisis. Premedication is recommended alpha-blockers.

  • Patients with autoimmune diseases

We describe the cases of severe vasculitis or Stevens-Johnson-like syndrome in patients with a history of autoimmune disease.

  • myasthenia

The introduction of iodinated contrast agents may enhance the severity of the symptoms of myasthenia gravis.

  • Alcoholism

Acute or chronic form of alcohol can increase the permeability of the blood-brain barrier. Lightweight penetration of contrast agent into the brain, can lead to reactions on the part of the central nervous system.

Introduction under the lining of the brain to be attentive to patients with seizures in history, as they have an increased risk of seizures in connection with the introduction of Ultravist drug under the lining of the brain. It should be ready for the treatment of seizures.

Introduction into other body cavities Before hysterosalpingography pregnancy should be excluded. Inflammation of the bile duct or fallopian tubes may increase the risk of reactions following ERCP or hysterosalpingography.

Use during pregnancy and lactation Relevant well-controlled studies in pregnant women have not been conducted. During pregnancy, should be avoided whenever possible radiological examinations. The benefits of any X-ray examination, with or without contrast agent should be beskrivelseanmeldelsermere carefully compared with the possible risk. At the same time the results of animal studies indicate no danger of Iopromide for diagnostic purposes in humans in regard to pregnancy, development of the embryo / fetus, childbirth and postnatal development.

Safety of Ultravist drug in infants who are breastfed, has not been studied. Ultravist excretion in breast milk is negligible, and it is unlikely to pose npp cycle a danger to infants.

nandrolone side effects

It has enterosorbiruyuschee, detoxication and antidiarrhoeal effect. It refers to a group of polyvalent physical and chemical antidotes. Has a high surface activity, it absorbs poisons and toxins from the gastrointestinal tract before the suction, namely, alkaloids, glycosides, hypnotics, barbiturates and other drugs used for general anesthesia.. And also, salts of heavy metals, toxins of bacterial, plant, animal, phenol derivatives, sulfonamides and gases.

Weakly adsorb acid and alkali (including iron salts, cyanides, malathion, methanol, ethylene glycol).

It does not irritate the mucous membrane of the gastrointestinal tract.

Special treatment (increased porosity) significantly increases the absorbent surface of the carbon.

 

Indications for use:

As enterosorbiruyuschee means for detoxification at exo and endogenous intoxications:

• flatulence,
• Dyspepsia,
• the processes of decay, fermentation, hypersecretion nandrolone side effects of mucus and gastric juice:
• diarrhea.
• poisoning by chemicals and drugs (including organophosphate and organochlorine compounds, psychotropic drugs),
• poisoning alkaloids, glycosides, salts of heavy metals,
• Food poisoning; food poisoning, dysentery, salmonellosis,
• alcohol withdrawal syndrome.

As enterosorbiruyuschee agents in the treatment of the drug is indicated for:

• burn disease at the stage of toxemia and septic;
• Renal failure,
• chronic hepatitis, acute viral hepatitis, cirrhosis,
• atopic dermatitis,
• bronchial asthma,
• gastritis, chronic cholecystitis, enterocolitis, holetsistopankreatit;
• the treatment of allergic diseases,
• the treatment of disorders metabolism,
• Treatment of intoxication in cancer patients during radiotherapy and chemotherapy;
• Preparation for radiographic and endoscopic studies (to reduce the concentration of gases in the intestines).

 

Contraindications:

Hypersensitivity, erosive and ulcerative nandrolone side effects lesions of the gastrointestinal (including gastric ulcer and 12 – duodenal ulcer, ulcerative colitis), bleeding from the gastrointestinal tract. Children under 3 years old.

Pregnancy:

During pregnancy and lactation, always consult with your doctor before taking Ultra – adsorption.

 

Dosage and administration:

Capsule taken orally with a small amount of water for 1 to 2 hours before or 1 to 2 hours after ingestion, and other drugs. Do not use zapivaniya for other beverages (coffee, tea, juice and others.), since they reduce the effectiveness of the drug.

When dyspepsia, flatulence –
adults – from 5 to 10 capsules (2.1 g), 3-4 times a day. The course of treatment 3 -7 days.
The course of treatment in cases involving the processes of fermentation and putrefaction in the intestines, increased secretion of gastric juice, lasts 1-2 weeks. Adults – 10-16 capsules up to 3 times a day (10 grams). Children 7-14 years – 2 – 3 capsules to receive up to 4 – 5 times a day (7 g).
Children from 3 to 7 years old – 1 – 2 capsules 3 times a day (5 g), or by a physician .

Side effects:

Dyspepsia, constipation or diarrhea; long-term use – vitamin deficiencies, decreased gastrointestinal absorption of nutrients (fat, protein) hormone. Long-term use, and taking high doses of Ultra – adsorption can affect the digestion and metabolism, as the drug adsorbs enzymes, vitamins and minerals.

 

Interaction with other drugs:

Reduces the effectiveness of drugs taken simultaneously, including antitoxic drugs, the effect of which develops after suction (methionine, etc.). It reduces the effectiveness of drugs acting on the mucous membrane of the gastro – intestinal tract (including ipecac and Thermopsis).

 

Special instructions:

In the treatment of intoxication must create nandrolone side effects excess carbon in the stomach (before it wash) and gut (stomach after washing). Reducing the carbon concentration in the medium promotes desorption related substance and its absorption (repeated gastric lavage and charcoal appointment is recommended to prevent the resorption of the released substances). The presence of food in the gastrointestinal mass -kishechnom tract requires the introduction of activated carbon in high doses because the contents of the digestive tract is absorbed carbon and its activity is reduced. If the poisoning is caused by substances involved in the enterohepatic circulation (cardiac glycosides, indomethacin, morphine and others. Opioids), you must use coal for a few days. When using the drug more than 10-14 days is necessary prophylactic vitamin and calcium supplements (only under medical supervision).

Ultra – adsorption should be stored separately from substances emitting into the atmosphere of gases or vapors. Storage in air (especially wet) reduces the sorption capacity of coal.

Application of Ultra – adsorption may lead to staining of the chair in black, which is not a clinical symptom.

testosterone phenylpropionate

Relationship to plasma proteins – 95%. Omeprazole is almost completely metabolized in the liver. It is an inhibitor of testosterone phenylpropionate enzyme system. The half-life after intravenous administration is 40 minutes and does not change during prolonged treatment. Excretion by the kidneys (70-80%) and the bile (20-30%). In chronic renal insufficiency excretion is reduced in proportion to the decrease  in creatinine clearance.

Indications

  • Gastric ulcer and duodenal ulcer;
  • Reflux esophagitis;
  • Erosive-ulcerative lesions of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drugs testosterone phenylpropionate, stress ulcer;
  • Erosive-ulcerative lesions of gastric and duodenal ulcers associated with Helicobacter pylori (in combination with antibiotics, in the complex therapy);
  • Zollinger-Ellison syndrome;
  • Prevention of acidic stomach contents entering the respiratory tract during general anesthesia (Mendelson’s syndrome).

Contraindications:
Hypersensitivity to the drug, children’s age, the period of lactation. With care – renal and / or hepatic impairment.

Pregnancy and lactation period
Caution should be exercised when administering the drug to pregnant women. Treatment indicated in cases where the potential beneficial effect of the drug to the mother justifies the risk to the fetus. During treatment breast feeding is not recommended.

Dosing and Administration
In case of impossibility of oral therapy in patients with gastric ulcer and duodenal ulcers or reflux oesophagitis recommended to prescribe intravenous Ultop the drug at a dose of 40 mg once a day. In patients with Zollinger-Ellison syndrome is recommended initial intravenous ultop a dose of 60 mg per day. Doses are selected individually, sometimes requires the introduction of a higher dose. If the value of a daily dose greater than 60 mg, the dose should be divided into two administrations.
The infusion solution Ultop drug is administered intravenously for 20-30 minutes. Recommended that the infusion solution be administered immediately after preparation. Patients with impaired renal function – no need to carry out a correction dose. Patients with impaired liver function – the half-life of omeprazole is longer, it is recommended to decrease the daily dose of 10-20 mg. Elderly patients dose adjustment is not required.

Preparation ultop infusion solution. Dissolve the lyophilized powder of omeprazole in 100 ml infusion of 5% dextrose (glucose) or in a 100 ml infusion of saline. Infusion solution of 5% dextrose should be used within 6 hours. Infusion solution at physiological saline should be used within 12 hours.

 

Side effect On the part of the digestive system: diarrhea or constipation, nausea, vomiting, flatulence, abdominal pain, dry mouth, taste disturbances, stomatitis, transient increase in activity of “liver” enzymes in the plasma; in patients with previous severe liver disease – hepatitis (including jaundice..), abnormal liver function. From the nervous system: headache, dizziness, agitation, drowsiness, insomnia, paresthesias, depression, hallucinations; in patients with severe concomitant somatic diseases, patients with previous severe liver disease – encephalopathy. From the musculoskeletal system:muscle weakness, myalgia, arthralgia. Hematopoietic system: leukopenia, thrombocytopenia; . in some cases – agranulocytosis, pancytopenia For the skin: itching, skin rash; in some cases – photosensitivity, erythema multiforme, alopecia. Allergic reactions: urticaria, angioedema, bronchospasm, interstitial nephritis, anaphylactic shock, fever. Other: visual testosterone phenylpropionate disturbances, peripheral edema, increased sweating, gynecomastia; seldom – formation of gastric glandular cysts during long-term treatment (a consequence of inhibiting the secretion of hydrochloric acid, is benign, reversible). If Ultop used for a short period of time, side effects are rare and has a mild and transient. The most common side effects noted in the beginning of treatment. During prolonged treatment reduces the frequency of side effects. Side effects observed severe very rare. If they develop, treatment should be interrupted. The incidence of side effects in patients older than 65 years is the same as in younger patients.

Overdose symptoms: pain in the abdominal region, drowsiness, headache, dizziness, increased sweating, dry mouth, palpitations, blurred vision. Possible convulsions, difficulty breathing, and low body temperature. There is no specific antidote. Treatment is symptomatic. Hemodialysis is not effective enough.

Interaction with other medicinal products
interaction of omeprazole with other drugs is rare. There is a possibility of interaction with drugs that are metabolized in the liver with the participation testosterone phenylpropionate of the enzyme cytochrome P450. The concentrations in the blood plasma of diazepam, phenytoin, nifedipine, warfarin, aminopyrine, antipyrine and disulfiram may increase. As a rule, this increase is clinically insignificant for normal doses of omeprazole.Nevertheless, it is advisable to monitor the patients in the early or canceling treatment ultop, and if necessary to adjust the dose of phenytoin, diazepam, warfarin and disulfiram.
When concomitant administration of clarithromycin concentrations of clarithromycin and serum omeprazole increased.
Increasing the pH of gastric juice can result in reduce the bioavailability of ampicillin, ketoconazole, itraconazole and iron preparations.
Co-administration of omeprazole and digoxin to healthy individuals increases the bioavailability of digoxin by 10% due to the increased pH in the stomach.
The effectiveness of cyclosporin and prednisolone can be reduced. So sometimes you need to adjust the dose of cyclosporine.
When concomitant administration of antacids, amoxicillin, digoxin, theophylline, lidocaine, quinidine, metoprolol or propranolol clinically significant interaction has not been established.

Cautions
Before therapy is necessary to exclude the presence of malignant process (especially gastric ulcer), t. To. The treatment, masking symptoms, may delay correct diagnosis.
For elderly patients the dose adjustment is not required. Bioavailability of omeprazole is increased in patients with cirrhosis of the liver, but not marked increase in toxicity. The daily dose should not exceed 20 mg.
For patients with kidney disease a dose adjustment is required. Dialysis patients with chronic kidney disease does not affect the pharmacokinetic properties of omeprazole. Effects testosterone phenylpropionate  on ability to drive and use other mechanisms in normal doses the drug testosterone phenylpropionate has no effect on the speed of psychomotor reactions and concentration.